Primary neuroendocrine carcinoma of the male breast is an exceptionally rare entity, with fewer than 50 cases documented in ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated ...